BC-3195 is under clinical development by BioCity Biopharma and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, Phase I drugs for Metastatic Ovarian Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BC-3195’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BC-3195 overview
BC-3195 is under development for the treatment of metastatic solid tumors like head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, breast cancer, non- small cell lung cancer, endometrial cancer, urothelial cancer, colorectal cancer, ovarian cancer, pancreatic cancer and prostate cancer. The therapeutic candidate is a novel antibody drug conjugate contains the payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc). It is administered through intravenous route. It is acts by targeting CDH3.
BioCity Biopharma overview
BioCity Biopharma (BioCity) is a clinical-stage biopharmaceutical company. It discovers and develops novel and modality-independent therapeutics including small molecules, monoclonal, and bispecific antibodies for cancer and autoimmune disorders. The company’s lead product candidate, SC0062, an endothelin receptor type A antagonist, for the treatment of immunoglobulin A (IgA) and diabetic kidney disease (DKD). BioCity’s pipeline includes oncology drug candidates such as BC3195 and BC2027 to treat solid tumors; SC0245 for small cell lung cancer; SC0191 to treat ovarian cancer; and BC3402 for hepatocellular carcinoma (HCC). The company operates in China and the US. BioCity is headquartered in Wuxi, Jiangsu, China.
For a complete picture of BC-3195’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
